# HHS Draft Policy Names KPV Among Six Compounding Peptides, But It Is Not FDA Approval

> A telemedicine compounding clinic announced that KPV is named in a 2026 HHS draft interim enforcement-discretion policy for certain patient-specific 503A peptide compounding. The draft covers KPV acetate only in oral and topical forms under specified conditions, and is not an FDA approval.

- Date: 2026-11-13 · published 2026-11-14T00:11:30.576Z
- Category: policy · region US · magnitude low
- Page: https://feedsoft.ai/events/98601-hhs-draft-policy-names-kpv-among-six-compounding-peptides-but-it-is-not-fda
- Commodities: [Lysine](https://feedsoft.ai/c/LYSINE.md)

## Why it matters

This story concerns pharmaceutical compounding policy and has no plausible effect on feed grains, oilseeds, livestock feed ingredients or their prices.

## Sources

- thepeptidenewsroom.com: https://www.thepeptidenewsroom.com/hhs-draft-policy-names-kpv-among-six-compounding-peptides-but-it-is-not-fda-appr/

---
Data from Feedsoft AI (https://feedsoft.ai/). For information only; not investment advice.